Resistance mutations that distinguish HIV-1 envelopes with discordant VRC01 phenotypes from multi-lineage infections in the HVTN703/HPTN081 trial: implications for cross-resistance

Paula Marantz Cohen, Bronwen E. Lambson, Nonhlanhla N. Mkhize, Chivonne Moodley, Anna Yssel, Thandeka Moyo-Gwete, Talita York, Asanda Gwashu-Nyangiwe, Nonkululeko Ndabambi, Ruwayhida Thebus, Michal Juraska, Allan C. deCamp, Brian D. Williamson, Craig A. Magaret, Peter B. Gilbert, Dylan H. Westfall, Wenjie Deng, James I. Mullins, Lynn Morris, Carolyn Williamson, Penny L. MooreJournal of Virology 2025 · DOI

TL;DR

This study investigates how HIV-1 develops resistance to VRC01, a promising broadly neutralizing antibody (bNAb) used in prevention trials. By analyzing breakthrough infections in participants who received VRC01, researchers identified diverse mutations conferring resistance, often present in the transmitted virus itself, and found that resistance to VRC01 doesn't necessarily mean resistance to newer, more potent bNAbs.

What Problem Does This Paper Address?

The development of effective HIV-1 prevention strategies, particularly those relying on broadly neutralizing antibodies (bNAbs), faces a significant hurdle: viral resistance. While bNAbs like VRC01 have shown promise in preventing infection by sensitive strains, understanding the genetic mechanisms by which HIV-1 evades these antibodies is crucial for designing more robust vaccines and antibody-based therapies. The Antibody Mediated Prevention (AMP) trials, which administered VRC01, provided a unique opportunity to study breakthrough infections and identify the viral mutations responsible for VRC01 resistance. This paper specifically addresses the question of what mutations distinguish HIV-1 variants that are sensitive to VRC01 from those that are resistant, especially in cases where multiple viral lineages with differing sensitivities are present within a single individual.

Methods

The researchers employed a multi-pronged approach:

  • Deep Sequencing: HIV-1 env genes from breakthrough infections in six participants from the HVTN703/HPTN081 AMP trial were deep sequenced. This allowed for the identification of multiple viral lineages within individuals.
  • Phylogenetic Analysis: Phylogenetic trees were constructed to visualize the evolutionary relationships between the sequenced viral env genes and to identify distinct lineages within each participant.
  • Site-Directed Mutagenesis and Chimera Construction: To pinpoint the specific mutations responsible for VRC01 resistance, researchers used site-directed mutagenesis to revert suspected resistance mutations in resistant viral clones back to the sensitive form. In cases where multiple mutations were involved, they constructed chimeric viruses by swapping entire functional regions (like the β23-V5 loop) between sensitive and resistant clones.
  • Pseudovirus Production and Neutralization Assays: Engineered viral env genes were used to produce pseudoviruses. These pseudoviruses were then tested against VRC01 and a panel of other CD4-binding site bNAbs to assess their neutralization sensitivity. This allowed for the direct comparison of the VRC01 sensitivity of wild-type, mutated, and chimeric viruses.

Datasets

The study utilized HIV-1 env gene sequences obtained from participants in the HVTN703/HPTN081 AMP trial who experienced breakthrough infections despite VRC01 administration. These sequences were generated through deep sequencing of plasma RNA collected at the first HIV-1 RNA-positive visit. The study focused on six specific participants with multi-lineage infections exhibiting discordant VRC01 sensitivity.

Key Insights and Ideas

  • Diverse Escape Pathways: HIV-1 doesn't rely on a single "magic bullet" mutation to escape VRC01. Instead, resistance can emerge through multiple distinct mutational pathways affecting different regions of the viral envelope.
  • Transmitted Resistance: In many cases, VRC01 resistance wasn't an evolutionary adaptation that occurred after infection but was a property of the virus that was transmitted to the individual in the first place, present in one of the multiple founding lineages.
  • VRC01 Resistance Doesn't Mean Total bNAb Resistance: While VRC01-resistant viruses showed reduced sensitivity to VRC01, they generally retained sensitivity to other CD4-binding site bNAbs, particularly newer, more potent ones. This suggests that a combination of bNAbs could be more effective in overcoming resistance.
  • Structural Clues: Mutations conferring resistance were often found in key regions of the HIV-1 envelope protein that interact with VRC01, including loop D, the CD4-binding loop, and the β23-V5 loop.

Key Results

  • Six Participants Studied: Six individuals from the AMP trial with breakthrough infections and multiple viral lineages showing discordant VRC01 sensitivity were analyzed.
  • Single Mutations Can Restore Sensitivity: In four out of six participants, a single amino acid mutation was sufficient to restore partial or full VRC01 sensitivity to the resistant viral clone.
  • Complex Resistance in One Case: In one participant, the entire β23-V5 loop needed to be transferred from a sensitive to a resistant clone to restore partial sensitivity.
  • No Clear Mutations in One Case: For one participant, the resistant and sensitive clones differed by over 100 amino acids, making it impossible to pinpoint specific resistance mutations.
  • Reduced Potency, Not Complete Loss of Sensitivity: VRC01-resistant viruses generally retained sensitivity to other CD4-binding site bNAbs, although their neutralization potency was often reduced compared to VRC01-sensitive viruses. This reduction was particularly pronounced for some participants and certain antibodies.

Limitations and Future Work

  • Limited Sample Size: The study focused on only six participants, which limits the generalizability of the findings.
  • Participant-Specific Resistance: The specific mutations conferring resistance varied significantly between participants, highlighting the complexity of HIV-1 evolution.
  • Fitness Cost of Resistance: While previous studies suggest VRC01 resistance mutations can incur a fitness cost, this study did not extensively investigate this aspect. Future work could explore the persistence of these mutations in the context of waning bNAb levels and whether they indeed impose a fitness cost.
  • Need for Broader Panels: The authors suggest expanding the analysis to larger panels of viruses to better understand the increasing prevalence of VRC01 resistance in the general population.
  • Combinatorial Approaches: Future research should investigate the impact of combining different bNAbs to overcome resistance and achieve more comprehensive protection. Further studies are also needed to identify additional mutations and their impact on bNAb sensitivity.

Summary updated

Abstract

The Antibody Mediated Prevention (AMP) trials showed that passively infused VRC01, a broadly neutralizing antibody (bNAb) targeting the CD4 binding site (CD4bs) on the HIV-1 envelope protein (Env), protected against neutralization-sensitive viruses. We identified six individuals from the VRC01 treatment arm with multi-lineage breakthrough HIV-1 infections from HVTN703, where one variant was sensitive to VRC01 (IC<sub>50</sub> < 25 ug/mL) but another was resistant. By comparing Env sequences of resistant and sensitive clones from each participant, we identified sites predicted to affect VRC01 neutralization and assessed the effect of their reversion in the VRC01-resistant clone on neutralization sensitivity. In four pairs, a single mutation restored partial or full sensitivity to VRC01, whereas in the fifth participant, transfer of the entire [Formula: see text]23-V5 loop was required. No VRC01 resistance mutations could be identified in the sixth participant, with the discordant clones differing by >100 amino acids. Mutations responsible for the differential neutralization phenotypes occurred at distinct sites across Env, including residues in loop D, the CD4-binding loop, and between the [Formula: see text]23 and V5 loops. Analysis of deep sequencing <i>env</i> data showed that VRC01 resistance was likely the property of the acquired virus, rather than occurring through post-acquisition evolution. Although VRC01-resistant parental clones generally retained sensitivity to other CD4-binding site bNAbs, they were less potently neutralized than the VRC01-sensitive clones. In conclusion, VRC01 resistance mutations occurred through multiple mutational pathways, but sensitivity to second-generation CD4bs bNAbs was retained even in VRC01-resistant transmitted viruses, confirming the potential of these bNAbs for HIV-1 prevention studies.IMPORTANCEThe Antibody Mediated Prevention (AMP) trials provided proof of principle that VRC01, a CD4-binding site (CD4bs) HIV-1 broadly neutralizing antibody (bNAb), prevented the acquisition of antibody-sensitive viruses. However, understanding common mutations that confer resistance to different bNAbs provides important insights into the genetic barrier to resistance. Here we studied six AMP trial participants with breakthrough infections mediated by multiple viral lineages with discordant VRC01 sensitivity. We identified different mutations across the CD4-binding site that conferred resistance to VRC01 and showed that these mutations were a property of the acquired virus, rather than a result of post-acquisition evolution. We found that although VRC01 resistance was associated with reduced neutralization potency of second-generation CD4-binding site bNAbs, overall neutralization sensitivity was generally retained, which is promising for future use of such bNAbs in clinical trials.
BibTeX
@article{cohen2025resistance,
  author = {Paula Marantz Cohen and Bronwen E. Lambson and Nonhlanhla N. Mkhize and Chivonne Moodley and Anna Yssel and Thandeka Moyo-Gwete and Talita York and Asanda Gwashu-Nyangiwe and Nonkululeko Ndabambi and Ruwayhida Thebus and Michal Juraska and Allan C. deCamp and Brian D. Williamson and Craig A. Magaret and Peter B. Gilbert and Dylan H. Westfall and Wenjie Deng and James I. Mullins and Lynn Morris and Carolyn Williamson and Penny L. Moore},
  title = {{Resistance mutations that distinguish HIV-1 envelopes with discordant VRC01 phenotypes from multi-lineage infections in the HVTN703/HPTN081 trial: implications for cross-resistance}},
  journal = {Journal of Virology},
  year = {2025},
  doi = {10.1128/jvi.01730-24},
}
Figure